CN107427516B8 - 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 - Google Patents

7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 Download PDF

Info

Publication number
CN107427516B8
CN107427516B8 CN201680008476.7A CN201680008476A CN107427516B8 CN 107427516 B8 CN107427516 B8 CN 107427516B8 CN 201680008476 A CN201680008476 A CN 201680008476A CN 107427516 B8 CN107427516 B8 CN 107427516B8
Authority
CN
China
Prior art keywords
methods
salts
analogs
hexahydroimidazo
pyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680008476.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN107427516B (zh
CN107427516A (zh
Inventor
M·斯托格努
J·E·阿朗
R·S·波托夫
B·R·纳拉罕楚
G·L·奥尔森
Y·孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoceutics Inc
Original Assignee
Provid Pharmaceuticals Inc
Oncoceutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provid Pharmaceuticals Inc, Oncoceutics Inc filed Critical Provid Pharmaceuticals Inc
Priority to CN202110266214.3A priority Critical patent/CN113149985B/zh
Publication of CN107427516A publication Critical patent/CN107427516A/zh
Application granted granted Critical
Publication of CN107427516B publication Critical patent/CN107427516B/zh
Publication of CN107427516B8 publication Critical patent/CN107427516B8/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9413—Dopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5756—Prolactin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
CN201680008476.7A 2015-01-30 2016-01-29 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 Active CN107427516B8 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110266214.3A CN113149985B (zh) 2015-01-30 2016-01-29 六氢咪唑并吡啶并嘧啶酮、其类似物和盐、及其治疗用途

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562109737P 2015-01-30 2015-01-30
US62/109,737 2015-01-30
US201562148844P 2015-04-17 2015-04-17
US62/148,844 2015-04-17
US201562233757P 2015-09-28 2015-09-28
US62/233,757 2015-09-28
PCT/US2016/015817 WO2016123571A1 (en) 2015-01-30 2016-01-29 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one, analogs and salts thereof and their use in therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110266214.3A Division CN113149985B (zh) 2015-01-30 2016-01-29 六氢咪唑并吡啶并嘧啶酮、其类似物和盐、及其治疗用途

Publications (3)

Publication Number Publication Date
CN107427516A CN107427516A (zh) 2017-12-01
CN107427516B CN107427516B (zh) 2021-02-26
CN107427516B8 true CN107427516B8 (zh) 2021-04-09

Family

ID=56544438

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680008476.7A Active CN107427516B8 (zh) 2015-01-30 2016-01-29 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
CN202110266214.3A Active CN113149985B (zh) 2015-01-30 2016-01-29 六氢咪唑并吡啶并嘧啶酮、其类似物和盐、及其治疗用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110266214.3A Active CN113149985B (zh) 2015-01-30 2016-01-29 六氢咪唑并吡啶并嘧啶酮、其类似物和盐、及其治疗用途

Country Status (27)

Country Link
US (6) US9845324B2 (https=)
EP (4) EP3250208B1 (https=)
JP (4) JP6802172B2 (https=)
KR (3) KR102856422B1 (https=)
CN (2) CN107427516B8 (https=)
AU (4) AU2016211243B2 (https=)
BR (1) BR112017016487B1 (https=)
CA (3) CA2975476C (https=)
CY (1) CY1123616T1 (https=)
DK (2) DK3250208T3 (https=)
EA (1) EA037552B1 (https=)
ES (2) ES2839401T3 (https=)
FI (1) FI3805222T3 (https=)
HR (2) HRP20250250T1 (https=)
HU (2) HUE052821T2 (https=)
IL (5) IL312936A (https=)
LT (2) LT3805222T (https=)
MA (2) MA41434B1 (https=)
MD (2) MD3250208T2 (https=)
MX (3) MX2021001096A (https=)
PL (2) PL3250208T3 (https=)
PT (2) PT3250208T (https=)
RS (2) RS61243B1 (https=)
SG (2) SG11201706062TA (https=)
SI (2) SI3805222T1 (https=)
SM (2) SMT202000696T1 (https=)
WO (1) WO2016123571A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052821T2 (hu) 2015-01-30 2021-05-28 Oncoceutics Inc 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
RS66519B1 (sr) * 2016-01-29 2025-03-31 Oncoceutics Inc Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
IL297201A (en) 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3033667A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US20200129596A1 (en) * 2017-03-13 2020-04-30 City Of Hope m6A mRNA MODIFICATION IN CANCER TREATMENT
EP3589745A1 (en) * 2018-04-11 2020-01-08 Chemestmed Ltd. A method of modulating the rna methylation
TWI910104B (zh) 2019-03-26 2026-01-01 日商富士軟片股份有限公司 對屬於ｙｔｈｄｃ家族之蛋白質的表現或功能之抑制劑之用途、及篩選抑制ｂ型肝炎病毒蛋白質產生的物質之方法
BR112022015011A2 (pt) * 2020-01-29 2022-09-20 Corcept Therapeutics Inc Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical
EP4192467A1 (en) * 2020-08-06 2023-06-14 Eötvös Loránd Tudományegyetem Synthesis of novel imipridone derivatives and their evaluation for their anticancer activity
EP4223876A4 (en) 2020-09-30 2025-12-10 Fujifilm Corp DOUBLE-STRANDED RNA THAT INHIBITS THE PRODUCTION OF A HEPATITIS B VIRUS PROTEIN, AND PHARMACEUTICAL COMPOSITION
KR20230118855A (ko) * 2020-11-13 2023-08-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 IRE1α 억제제 및 이의 용도
CN113100233B (zh) * 2021-04-19 2022-02-08 中国农业科学院植物保护研究所 芳甲羟肟酸及其衍生物作为几丁质脱乙酰基酶抑制剂及植物抗真菌剂的应用
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
EP4698146A1 (en) * 2023-04-20 2026-02-25 Institut Gustave-Roussy Liquid and solid compositions of imipridone derivatives
CN119306718A (zh) * 2023-07-11 2025-01-14 中科中山药物创新研究院 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用
CN117599041B (zh) * 2024-01-22 2024-05-03 中国人民解放军军事科学院军事医学研究院 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途
WO2025250553A1 (en) * 2024-05-28 2025-12-04 Chimerix, Inc. Solid state forms of imipridone derivative
EP4684834A1 (de) * 2024-07-26 2026-01-28 BRIU GmbH Kristallformen onkologisch wirksamer imipridone und verfahren zu deren herstellung
CN119198986B (zh) * 2024-11-28 2025-03-11 淄博高新技术产业开发区生物医药研究院 化药中n-亚硝基双氯芬酸基因毒杂质含量的分析方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228183A (zh) * 2005-05-24 2008-07-23 健泰科生物技术公司 使用低温下结晶纯化apo-2配体/trail的方法
US20140335048A1 (en) * 2013-03-13 2014-11-13 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
CN104860948A (zh) * 2015-05-15 2015-08-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2015153468A1 (en) * 2014-03-31 2015-10-08 The Scripps Research Institute Pharmacophore for trail induction

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2150062A1 (de) * 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
US4642345A (en) 1980-08-14 1987-02-10 Mead Johnson & Company 6,7-dihydro-3H-imidazo[1,2-a]-purine-9(4H)-ones
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US7635690B2 (en) 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
AU2003253186A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
WO2004082570A2 (en) 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d2 (drd2)
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070026402A1 (en) 2003-07-08 2007-02-01 Noble Ernest P Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US20080221135A1 (en) 2005-05-13 2008-09-11 Bristol-Myers Squibb Company Combination therapy
US8088895B2 (en) 2006-10-18 2012-01-03 Chemocentryx, Inc. Antibodies that bind CXCR7 epitopes
WO2010033315A1 (en) 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
CA2746129A1 (en) 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combination chemotherapy of nanoparticulate taxanes and inhibitors of pro-survival and/or inflammatory signals
US9724337B2 (en) 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
WO2011144622A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh 1h - imidazo [4, 5 - c] quinolines
US8735386B2 (en) 2010-07-23 2014-05-27 Boehringer Ingelheim International Gmbh Aminopyrazoloquinazolines
EP2694678A2 (en) * 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
US20130102595A1 (en) * 2011-04-15 2013-04-25 Curis, Inc. Treatment of cancers having k-ras mutations
EP3679934B1 (en) * 2011-04-29 2024-06-05 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
SI2968294T1 (sl) * 2013-03-13 2019-08-30 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo(1,2-A)pirido (4,3-D)pirimidin-5(3H)-on za uporabo pri zdravljenju raka
KR102318238B1 (ko) * 2013-11-15 2021-10-26 온코슈틱스 인코포레이티드 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조[1,2-a]피리도[3,4-e]피리미딘-5(1H)-온, 이의 염 및 이의 용도
KR20150114239A (ko) * 2014-04-01 2015-10-12 제일모직주식회사 내열성 및 착색성이 향상된 열가소성 수지 조성물
HUE052821T2 (hu) * 2015-01-30 2021-05-28 Oncoceutics Inc 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101228183A (zh) * 2005-05-24 2008-07-23 健泰科生物技术公司 使用低温下结晶纯化apo-2配体/trail的方法
US20140335048A1 (en) * 2013-03-13 2014-11-13 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, Salts Thereof and Methods of Using the Same in Combination Therapy
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
WO2015153468A1 (en) * 2014-03-31 2015-10-08 The Scripps Research Institute Pharmacophore for trail induction
CN104860948A (zh) * 2015-05-15 2015-08-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用

Also Published As

Publication number Publication date
SMT202500087T1 (it) 2025-03-12
RS66551B1 (sr) 2025-03-31
RS61243B1 (sr) 2021-01-29
EP3805222A3 (en) 2021-06-30
KR102618971B1 (ko) 2023-12-27
AU2024203421A1 (en) 2024-06-13
EA201791727A1 (ru) 2018-01-31
JP2025186367A (ja) 2025-12-23
EP4516359A3 (en) 2025-04-23
SG10201803508WA (en) 2018-05-30
CA3209515A1 (en) 2016-08-04
NZ733994A (en) 2024-04-26
JP2021050209A (ja) 2021-04-01
CN113149985A (zh) 2021-07-23
MA41434B1 (fr) 2021-03-31
US20190194201A1 (en) 2019-06-27
AU2020286168B2 (en) 2022-06-09
US20220017519A1 (en) 2022-01-20
CY1123616T1 (el) 2022-03-24
ES2839401T3 (es) 2021-07-05
IL274135A (en) 2020-06-30
US10266533B2 (en) 2019-04-23
US20180072729A1 (en) 2018-03-15
CA2975476A1 (en) 2016-08-04
AU2022228096A1 (en) 2022-09-29
SI3805222T1 (sl) 2025-04-30
CA2975476C (en) 2023-10-03
MX379425B (es) 2025-03-11
LT3805222T (lt) 2025-02-10
IL288525A (en) 2022-01-01
EP3250208A1 (en) 2017-12-06
IL295286A (en) 2022-10-01
MX2021001096A (es) 2023-01-17
HRP20201949T1 (hr) 2021-01-22
HRP20250250T1 (hr) 2025-03-28
HUE070309T2 (hu) 2025-05-28
EP4512483A3 (en) 2025-04-23
KR20250134216A (ko) 2025-09-09
EP3250208A4 (en) 2018-10-03
MA41434A (fr) 2017-12-06
SMT202000696T1 (it) 2021-01-05
AU2020286168B8 (en) 2022-09-22
IL295286B1 (en) 2024-06-01
JP2024160257A (ja) 2024-11-13
MD3805222T2 (ro) 2025-04-30
JP2018503663A (ja) 2018-02-08
BR112017016487B1 (pt) 2023-11-07
AU2016211243A1 (en) 2017-08-10
IL295286B2 (en) 2024-10-01
PT3250208T (pt) 2021-01-06
PL3805222T3 (pl) 2025-04-07
NZ772369A (en) 2024-07-05
NZ772080A (en) 2024-07-05
US20170096431A1 (en) 2017-04-06
IL253689B (en) 2020-05-31
FI3805222T3 (fi) 2025-01-22
IL253689A0 (en) 2017-09-28
ES3009132T3 (en) 2025-03-26
US9845324B2 (en) 2017-12-19
EP3805222B1 (en) 2024-12-04
CN113149985B (zh) 2025-01-28
US11976068B2 (en) 2024-05-07
KR102856422B1 (ko) 2025-09-04
CN107427516B (zh) 2021-02-26
MD3250208T2 (ro) 2021-02-28
MX2017009841A (es) 2018-02-09
SI3250208T1 (sl) 2021-01-29
JP7579684B2 (ja) 2024-11-08
IL288525B (en) 2022-09-01
EP4512483A2 (en) 2025-02-26
PL3250208T3 (pl) 2021-04-06
LT3250208T (lt) 2021-01-25
MX2023000782A (es) 2023-02-14
JP6802172B2 (ja) 2020-12-16
AU2024203421B2 (en) 2026-03-12
US20240270746A1 (en) 2024-08-15
CA3209519A1 (en) 2016-08-04
SG11201706062TA (en) 2017-08-30
MA55402A (fr) 2022-02-02
AU2016211243B2 (en) 2020-09-10
DK3805222T3 (da) 2025-01-06
IL312936A (en) 2024-07-01
MA55402B1 (fr) 2025-02-28
WO2016123571A1 (en) 2016-08-04
AU2020286168A1 (en) 2021-01-07
EA037552B1 (ru) 2021-04-13
IL274135B (en) 2022-01-01
EP3250208B1 (en) 2020-09-30
EP3805222A2 (en) 2021-04-14
HUE052821T2 (hu) 2021-05-28
PT3805222T (pt) 2025-03-10
KR20240005186A (ko) 2024-01-11
US20250109133A1 (en) 2025-04-03
BR112017016487A2 (pt) 2018-04-10
CN107427516A (zh) 2017-12-01
DK3250208T3 (da) 2021-01-04
EP4516359A2 (en) 2025-03-05
KR20170109583A (ko) 2017-09-29

Similar Documents

Publication Publication Date Title
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
EP4353322A3 (en) Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
NZ711948A (en) Combination therapy with 7-benzyl-10-(2-methylbenzyl)-2,6,7,8,9,10-hexahydroimidazo[1,2-a]pyrido[4,3-d]pyrimidin-5(3h)-one
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
WO2015042078A3 (en) Substituted aminopyrimidine compounds and methods of use
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
WO2015048662A3 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
HK1255598A1 (zh) 咪唑并[4，5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
EP4480543A3 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
EA202090662A3 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
HRP20211653T1 (hr) 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci korištenja istih u kombiniranoj terapiji
WO2016100347A3 (en) Small molecule inhibitors of egfr and pi3k
EA201991877A3 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2- a]пиридо[3,4-e]пиримидин-5(1h)-он, его соли и способы применения
WO2015110491A3 (en) Pyrazolo[1,5-a]pyrimidines as antiviral compounds
WO2016010869A3 (en) FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2016022700A8 (en) Tlr-independent small molecule adjuvants
HRP20190961T1 (hr) Derivat tetrahidropirolo[3,4-d][1,3]tiazina kao inhibitor bace
WO2019028309A1 (en) AZAINDOLES AND THEIR METHODS OF USE
EA202190165A1 (ru) 7-БЕНЗИЛ-4-(2-МЕТИЛБЕНЗИЛ)-2,4,6,7,8,9-ГЕКСАГИДРОИМИДАЗО[1,2-a]ПИРИДО[3,4-e]ПИРИМИДИН-5(1Н)-ОН, ЕГО АНАЛОГИ И СОЛИ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ В ТЕРАПИИ
HK1254661A1 (zh) 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
TH158508A (th) อนุพันธ์ไพโรโล [3,2-d] ไพริมิดีนสำหรับการบำบัดของการติดเชื้อไวรัสและโรคอื่นๆ
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210222

Address after: Pennsylvania, USA

Applicant after: ONCOCEUTICS, Inc.

Address before: Pennsylvania, USA

Applicant before: ONCOCEUTICS, Inc.

Applicant before: PROVID PHARMACEUTICALS Inc.

CI03 Correction of invention patent
CI03 Correction of invention patent

Correction item: Patentee|Address|Patentee

Correct: ONCOCEUTICS, Inc.|Pennsylvania, USA

False: ONCOCEUTICS, Inc.|Pennsylvania, USA|PROVID PHARMACEUTICALS Inc.

Number: 09-02

Page: The title page

Volume: 37

Correction item: Patentee|Address|Patentee

Correct: ONCOCEUTICS, Inc.|Pennsylvania, USA

False: ONCOCEUTICS, Inc.|Pennsylvania, USA|PROVID PHARMACEUTICALS Inc.

Number: 09-02

Volume: 37